ge put podium
upgrad buy fv
note ge topic note late last year life scienc asset gener
electr ge-not follow elit busi within bio-product life
scienc market worth billion pay billion join
bio-product elit thermo fisher tmo-buy sartoriu ag
grow organ around instead expect earn
upsid manag busi note previous valu ge life
scienc lock within healthcar divis also highlight potenti
acquir prize ge asset given ge need rais cash
adjust model reflect accret debt issu rais rate buy
fair valu
ge acquir prize asset healthcar like amersham
whatman hyclon billion deal place
squar fastest grow healthcar segment bioproduct
product filtrat equip produc biotechnolog therapeut
expect market grow approxim annual global
therapeut market transit small molecul industri sale
life scienc valuat show market place higher valu
bioproduct busi large-cap tool compani like thermo danah
valu ev/ebitda estim bioproduct
compani univers averag estim seem
struck good valu ge ls acquisit price ebitda
purchas price billion also repres revenu
major pharma transform major biopharma earli year
transit exampl trillion global therapeut sale
biotechnolog base therapi approv highest
fda histori three regen medicin therapi approv
yet await clinic trial tool compani retrofit laboratori
instrument bioproduct firm enabl manufactur biolog
diagnost firm match patient right therapi
rais fair valu rate neutral
buy fv reach appli multipl ebitda
estim deduct estim debt per share
guid earn accret first year ownership
life scienc group typic valu around ev/ebitda expect
organ growth acceler ge ls
busi provid oper margin expans potenti
million except per share data
dental revenu assum growth quarter spin occur quarter management guid revenu growth rate refelect spin dental biz
impact foreign currenc
management guid cent fx/tariff headwind
total sale
earn jv
annual revenu break-out margin
total sale
revenu
